Why Gritstone Bio (GRTS) Stock Is Down 64% Today
Why Gritstone Bio (GRTS) Stock Is Down 64% Today
Gritstone bio Inc. (NASDAQ:GRTS) shares are trading lower by 64.2% to $0.07 during Thursday's session after the company announced it voluntarily filed for Chapter 11 restructuring.
Gritstone bio Inc.（納斯達克股票代碼：GRTS）宣佈自願申請第11章重組後，該公司股價在週四的交易中下跌了64.2％，至0.07美元。
What Else: Gritstone Bio says the company plans to use the court-supervised restructuring to preserve value while exploring strategic alternatives. Gritstone is in talks with a potential bidder or plan sponsor and hopes to present a deal to the court soon.
還有什麼：Gritstone Bio表示，該公司計劃利用法院監督的重組來保持價值，同時探索戰略替代方案。Gritstone正在與潛在的競標者或計劃發起人進行談判，並希望儘快向法院提交協議。
The company also says it remains focused on developing next-generation vaccines and immunotherapies, including its promising GRANITE cancer treatment, while continuing normal operations during the bankruptcy process. Gritstone added that the company aims to minimize the impact on employees, vendors and stakeholders through "first day" motions.
該公司還表示，它仍然專注於開發下一代疫苗和免疫療法，包括其有前途的GRANITE癌症治療方法，同時在破產過程中繼續正常運營。Gritstone補充說，該公司的目標是通過 「第一天」 動議將對員工、供應商和利益相關者的影響降至最低。
Read Also: Delta's Turbulent Q3: Mixed Results And Tech Troubles Cloud Holiday Outlook
另請閱讀：達美航空動盪的第三季度：業績喜憂參半和技術問題讓假日前景黯淡
According to data from Benzinga Pro, GRTS has a 52-week high of $3.33 and a 52-week low of $0.07.
根據Benzinga Pro的數據，GRTS的52周高點爲3.33美元，52周低點爲0.07美元。
